The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib
Open accessAbstract
BACKGROUND & AIMS: Neutrophils can either promote or inhibit tumor progression, depending on the tumor microenvironment, via release of cytokines. Neither the factors produced by tumor-associated neutrophils (TANs) nor their effects on tumor progression have been characterized. We investigated the roles of TANs in progression of hepatocellular carcinoma (HCC) using cell lines and immune cells isolated from patients. METHODS: We performed studies with HepG2, PLC/PRF/5, MHCC97H, and HCCLM3 human and Hepa1-6 and H22 mouse HCC cell lines; expression of chemokines and cytokines were knocked down with small hairpin RNAs. Cells were analyzed in chemotaxis assays and as growth as tumors in mice. HCC tissues and peripheral blood were collected from 20 patients undergoing curative resection or 20 healthy individuals (controls) in 2012 at Zhongshan Hospital in China. TANs and peripheral blood neutrophils (PBNs) were isolated and exposed to conditioned media from HCC cell lines; reverse-transcription polymerase chain reaction was used to quantify the expression of cytokines and chemokines. We collected neutrophils from another 60 patients undergoing curative resection for HCC in 2012 to measure the production of C-C motif chemokine ligand 2(CCL2) and CCL17. Patients were followed up until March 15, 2014. For immunohistochemical analyses, we collected HCC tissues and paired, adjacent, nontumor cirrhotic liver tissues from 832 HCC patients undergoing curative resection from 2006 through 2008. All patients were followed up until March 15, 2013. To study the effects of sorafenib, we collected clinical and pathology data from 46 patients who underwent curative resection in 2010. RESULTS: CCL2 and CCL17 were the cytokines most highly expressed by TANs and HCC cell-activated PBNs. Levels of CCL2 and CCL17 messenger RNAs and proteins were significantly higher in TANs than in PBNs, and increased in patients with HCC recurrence. CCL2 and CCL17 messenger RNA and proteins also increased when PBNs were exposed to conditioned media from HCC cell lines. Immunohistochemical analysis of a tissue microarray showed that CCL2+ and CCL17+ cells, which also expressed the neutrophil marker CD66b, were distributed throughout the HCC stroma, but not in tumor cells or the adjacent nontumor liver cells. The number of CCL2+ or CCL17+ TANs correlated with tumor size, microvascular invasion, tumor encapsulation, tumor differentiation, and stage. Patients whose tumors had lower levels of CCL2+ or CCL17+ cells had longer survival times than those with higher numbers of these cells. TAN-conditioned media, as well as recombinant CCL2 and CCL17, increased the migratory activity of the macrophages and T-regulatory (Treg) cells from patients or mice with HCC to a greater extent that PBN-conditioned media. Neutralizing antibodies against CCL2 and CCL17, or their receptors C-C chemokine receptor 2 and C-C chemokine receptor 4, reduced the migratory activities of macrophage and Treg cells. HCC cell lines injected into mice formed larger tumors when they were co-injected with TANs and formed more pulmonary metastases; these tumors were infiltrated by Ly6G+ cells, F4/80+ macrophages, and Foxp3+ Treg cells. In a phosphokinase array of human PBNs, levels of phosphorylated AKT and P38 increased after exposure to conditioned media from all 4 HCC cell types. Pharmacologic inhibitors of AKT and P38 inhibited secretion of CCL2 and CCL17 by these PBNs. In tumor-bearing mice, sorafenib increased the numbers of TANs and levels of CCL2 and CCL17 in tumors. HCC tissues from patients who received sorafenib before surgery contained more TANs than tissues from patients who did not receive sorafenib. In knockdown cells, HCC cell-derived CXCL5 was the strongest effector of neutrophil migration under hypoxic conditions. In mice, the combination of sorafenib and TAN depletion inhibited tumor growth and neovascularization to a greater extent than sorafenib alone. CONCLUSIONS: TANs recruit macrophages and Treg cells to HCCs to promote their growth, progression, and resistance to sorafenib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Neutrophils in the activation and regulation of innate and adaptive immunity
Mantovani, A., Cassatella, M. A., Costantini, C., & Jaillon, S. (2011) · Nature Reviews Immunology · doi:10.1038/nri3024 · Cited by 3,027
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Diagnosis and Treatment of Hepatocellular Carcinoma
El-Serag, H. B., Marrero, J. A., Rudolph, L., & Reddy, K. R. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.090 · Cited by 1,137
Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,110
Self-citationA CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085
Su, S., Liu, Q., Chen, J., Chen, J., Chen, F., He, C., Huang, D., Wu, W., Lin, L., Huang, W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.021 · Cited by 772
Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growth
Houghton, A. M., Rzymkiewicz, D. M., Ji, H., Gregory, A. D., Egea, E. E., Metz, H. E., Stolz, D. B., Land, S. R., Marconcini, L. A., Kliment, C. R., et al. (2010) · Nature Medicine · doi:10.1038/nm.2084 · Cited by 744
Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Hernandez–Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.002 · Cited by 722
Yang, P., Li, Q.-J., Feng, Y., Zhang, Y., Markowitz, G. J., Ning, S., Deng, Y., Zhao, J., Jiang, S., Yuan, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.023 · Cited by 536
Kuang, D.-M., Zhao, Q., Wu, Y., Peng, C., Wang, J., Xu, Z., Yin, X.-Y., & Zheng, L. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.041 · Cited by 499
MCP-1: Chemoattractant with a role beyond immunity: A review
Yadav, A., Saini, V., & Arora, S. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.07.006 · Cited by 488
Tumor associated macrophages and neutrophils in tumor progression
Galdiero, M. R., Garlanda, C., Jaillon, S., Marone, G., & Mantovani, A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24260 · Cited by 440
Queen, M. M., Ryan, R. E., Holzer, R. G., Keller-Peck, C. R., & Jorcyk, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1734 · Cited by 413
The chemokine system in cancer biology and therapy
Mantovani, A., Savino, B., Locati, M., Zammataro, L., Allavena, P., & Bonecchi, R. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.007 · Cited by 393
Zhou, S.-L., Dai, Z., Zhou, Z.-J., Wang, X.-Y., Yang, G.-H., Wang, Z., Huang, X.-W., Fan, J., & Zhou, J. (2012) · Hepatology · doi:10.1002/hep.25907 · Cited by 356
Self-citationLeukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues
Goodarzi, K., Goodarzi, M., Tager, A. M., Luster, A. D., & von Andrian, U. H. (2003) · Nature Immunology · doi:10.1038/ni972 · Cited by 354
Mano, Y., Shirabe, K., Yamashita, Y.-I., Harimoto, N., Tsujita, E., Takeishi, K., Aishima, S., Ikegami, T., Yoshizumi, T., Yamanaka, T., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318297ad6b · Cited by 311
Dumitru, C. A., Lang, S., & Brandau, S. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.02.005 · Cited by 303
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
De Bock, K., Mazzone, M., & Carmeliet, P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.83 · Cited by 293
Immunomonitoring and prognostic relevance of neutrophils in clinical trials
Donskov, F. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.02.001 · Cited by 293
Liang, Y., Zheng, T., Song, R., Wang, J., Yin, D., Wang, L., Liu, H., Tian, L., Fang, X., Meng, X., et al. (2013) · Hepatology · doi:10.1002/hep.26224 · Cited by 289
Tian, J., Tang, Z. Y., Ye, S. L., Liu, Y. K., Lin, Z. Y., Chen, J., & Xue, Q. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690769 · Cited by 281
Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Liang, J., Piao, Y., Holmes, L., Fuller, G. N., Henry, V., Tiao, N., & de Groot, J. F. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1279 · Cited by 280
Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection
Li, Y.-W., Qiu, S.-J., Fan, J., Zhou, J., Gao, Q., Xiao, Y.-S., & Xu, Y.-F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.044 · Cited by 268
Self-citationWislez, M., Rabbe, N., Marchal-Sommé, J., Milleron, B. J., Crestani, B., Mayaud, C. M., Antoine, M., Soler, P., & Cadranel, J. L. (2003) · PubMed · Cited by 243
Zhou, S.-L., Dai, Z., Zhou, Z.-J., Chen, Q., Wang, Z., Xiao, Y.-S., Hu, Z.-Q., Huang, X.-Y., Yang, G.-H., Shi, Y.-H., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgt397 · Cited by 195
Self-citationOn the cytokines produced by human neutrophils in tumors
Tecchio, C., Scapini, P., Pizzolo, G., & Cassatella, M. A. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.02.004 · Cited by 188
Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Li, X., Huang, X.-W., Wang, Z., Fan, J., Dai, Z., & Zhou, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.044 · Cited by 185
Self-citationBlivet-Van Eggelpoël, M.-J., Chettouh, H., Fartoux, L., Aoudjehane, L., Barbu, V., Rey, C., Priam, S., Housset, C., Rosmorduc, O., & Desbois-Mouthon, C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.019 · Cited by 181
Protumor and antitumor functions of neutrophil granulocytes
Brandau, S., Dumitru, C. A., & Lang, S. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-012-0344-6 · Cited by 158
Neutrophils promote motility of cancer cells via a hyaluronan‐mediated TLR4/PI3K activation loop
Wu, Y., Zhao, Q., Peng, C., Sun, L., Li, X., & Kuang, D. (2011) · The Journal of Pathology · doi:10.1002/path.2947 · Cited by 146
Wang, L., Tang, Z., Qin, L., Wu, X., Sun, H., Xue, Q., & Ye, S. (2000) · Hepatology · doi:10.1053/jhep.2000.8525 · Cited by 118
Functional role of chemokines in liver disease models
Sahin, H., Trautwein, C., & Wasmuth, H. E. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.168 · Cited by 107
Zhou, Z., Dai, Z., Zhou, S., Hu, Z., Chen, Q., Zhao, Y., Shi, Y., Gao, Q., Wu, W., Qiu, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2509 · Cited by 103
Self-citationPitfalls in der Klassifikation von Lebertumoren
Wittekind, C. (2006) · Der Pathologe · doi:10.1007/s00292-006-0834-1 · Cited by 100
Keates, A. C., Keates, S. E., Kwon, J. H., Arseneau, K. O., Law, D., Bai, L., Merchant, J. L., Wang, T. C., & Kelly, C. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107838200 · Cited by 95
Hypoxia. Regulation of NFκB signalling during inflammation: the role of hydroxylases
Oliver, K. M., Taylor, C. T., & Cummins, E. P. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2575 · Cited by 95
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Berasain, C. (2013) · Gut · doi:10.1136/gutjnl-2013-304564 · Cited by 94
Strell, C., Lang, K., Niggemann, B., Zaenker, K. S., & Entschladen, F. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.09.003 · Cited by 85
Gastrin-releasing peptide receptor (GRPR) mediates chemotaxis in neutrophils
Czepielewski, R. S., Porto, B. N., Rizzo, L. B., Roesler, R., Abujamra, A. L., Pinto, L. G., Schwartsmann, G., Cunha, F. Q., & Bonorino, C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110996109 · Cited by 75
Anti‐angiogenesis and metastasis: a tumour and stromal cell alliance
Moserle, L., & Casanovas, O. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12018 · Cited by 70
Kang, S., Xie, J., Ma, S., Liao, W., Zhang, J., & Luo, R. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.03.001 · Cited by 43
Cited by
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Metadata
- Authors
- Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Huang, X.-W., Wang, Z., Chen, E.-B., Fan, J., Cao, Y., Dai, Z., & Zhou, J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 150
- Issue
- 7
- Pages
- 1646-1658.e17
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2283284501
- Cited by
- 852
- References
- 49
- FWCI
- 23.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.